Compare Target Corporation (TGT) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Target Corporation vs TG Therapeutics Inc — how do they compare? Target Corporation trades at $138.64 (market cap $63.40B), while TG Therapeutics Inc trades at $54 (market cap $8.26B). The key difference: Target Corporation is far larger — about 7.7× TG Therapeutics Inc's market cap, and Target Corporation pays a 3.32% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| TGT | TGTX | |
|---|---|---|
Market Cap | $63.40B | $8.26B |
Sector | Consumer Cyclical | Health |
52-Week High | $141.19 | $59.06 |
52-Week Low | $83.68 | $26.39 |
Enterprise Value | $78.70B | $8.50B |
Dividend Yield | 3.32% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Target Corporation (TGT) trades at $138.50, down 0.8% on the day, with a bullish technical outlook supported by moving averages. The company maintains stable revenue near $106.6 billion (2025) and has beaten earnings estimates for three consecutive quarters. Recent news highlights new product collaborations and institutional buying interest, while analyst consensus leans slightly bullish with a $138.21 price target.
Target's investment case balances solid fundamentals against margin pressures. Opportunities include consistent dividend payments and market share gains in retail, but risks involve competitive pressures and potential consumer spending slowdowns. The stock offers value with a P/E of 18.44 but requires monitoring of net income margin trends.
TG Therapeutics (TGTX) trades at $53.96, down 1.6% today, with a bullish technical signal and strong profitability metrics including a 65.95% net income margin. Recent news highlights clinical progress, including a Phase 2 trial for Briumvi in schizophrenia (Zacks Investment Research, 2026-07-07) and positive Phase 1 data for subcutaneous Briumvi (GlobeNewsWire, 2026-06-03). However, earnings misses in Q4 2025 and Q1 2026 and a shareholder investigation (PRNewsWire, 2026-07-21) introduce volatility.
The outlook is mixed: analyst consensus is strongly bullish (84.6% buy ratings) with a $48.50 price target, but near-term risks from legal scrutiny and earnings inconsistency warrant caution. Upside hinges on successful drug trials and sales growth, while downside risks include legal outcomes and competitive pressures in the biotech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Target Corporation
With 1,926 stores (as of the end of fiscal 2021), Target is a leading American general merchandise retailer, offering a variety of products across several categories, including beauty and household essentials (26% of fiscal 2021 sales), food and beverage (19%), home furnishings and décor (19%), hardlines (18%), and apparel and accessories (17%). Most of Target's stores are large, averaging more than 125,000 square feet. The company has a significant e-commerce presence, deriving around 19% of sales from the channel (up from about 9% in fiscal 2019, before the pandemic). In addition to its namesake stores, Target owns Shipt, an online same-day delivery platform. After it exited Canada in 2015, virtually all of Target's revenue is generated from the United States.
Read more on TGT →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
